REG - Tristel PLC - VISICLEAN Product Launch

TristelAnnouncement

Thu 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250925:nRSY6721Aa&default-theme=true

RNS Number : 6721A  Tristel PLC  25 September 2025

TRISTEL plc

("Tristel" or the "Company")

 

VISICLEAN™ Product Launch

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products,
announces the launch of its new ultrasound probe decontamination product,
Tristel VISICLEAN™, the first detergent of its kind with colour technology,
enabling visible coverage and confirmation of high level disinfection.

 

Tristel VISICLEAN™ is deployed on the ultrasound probe, dying it pink, and
when exposed to Tristel ClO₂ via Tristel DUO ULT™, the pink dye
disappears, visibly verifying that the probe has been high level disinfected.
Tristel VISICLEAN™ is now available within the VISI Combination Pack, a
convenient, all-in-one solution for ultrasound probe decontamination.
Effective high-level disinfection begins with cleaning, which eliminates
organic matter and reduces microbes to ensure proper sterilisation. This is
performed manually and must be done each time. Tristel VISICLEAN™ is the
only cleaning solution with visible verification, ensuring full auditability
and compliance with protocols.

 

 

Tristel VISICLEAN™, DUO ULT™ and DRY WIPES™, the products within the
VISI Combination Pack

 

The VISI Combination Pack includes the Company's new product, Tristel
VISICLEAN™, along with two pre-existing products, Tristel DUO ULT™ &
Tristel DRY WIPES™. Together, these products enable clinicians to perform
manual decontamination procedures with confidence, precision, and audit-ready
traceability via Tristel's 3T™ digital platform. VISI Combination Packs are
now available to healthcare providers across the UK and are being launched
globally on a phased basis, as and when the Company secures the necessary
local regulatory clearances.

 

Tristel's proprietary chlorine dioxide chemistry is globally trusted for its
broad-spectrum efficacy and resistance-proof mechanism. With over 30 years of
experience in high-level disinfection, Tristel continues to remain at the
forefront of infection prevention.

 

Matt Sassone, CEO of Tristel plc, said: "We are pleased to launch Tristel
VISICLEAN™, as part of the VISI Combination Pack, delivering visible
cleaning, confirmed disinfection, and digital traceability, all in one
intuitive kit. The scope for these products is vast and the up-sell
opportunity from Tristel DUO ULT™ alone would result in 14 million cleaning
procedures per annum."

 

For further information please contact:

 Tristel plc                                                                Via Walbrook PR
 Matt Sassone, Chief Executive Officer                                      www.investors.tristel.com (https://investors.tristel.com/)
 Anna Wasyl, Chief Financial Officer

 Walbrook PR Ltd                                                            Tel: 020 7933 8780 or tristel@walbrookpr.com
 Paul McManus / Lianne Applegarth / Anna Dunphy    Mob: 07980 541 893/ 07584 391 303/ 07876 741 001

 Cavendish Capital Markets Ltd                                              Tel: 020 7220 0500
 Geoff Nash / Callum Davidson/Trisyia Jamaludin (Corporate Finance)
 Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

 

 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the
manufacture and supply of products using its unique proprietary chlorine
dioxide (ClO(2)) chemistry. The Company is a market leader in manual
decontamination of medical devices, supplying hospitals under the Tristel
(https://tristel.com/) brand, and under the Cache
(https://thecachecollection.com/) brand provides products for sporicidal
surface disinfection, a more sustainable alternative to commonly used
pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near
Cambridge, and operates globally employing approximately 270 people across 16
subsidiaries selling into 40+ countries. The Company targets double digit
revenue growth annually and an EBITDA margin of at least 25% and the business
is profitable, with no debt and has a progressive dividend policy.

 

The Company has been listed on the London Stock Exchange's AIM market since
2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit:
https://tristel.com (https://tristel.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PRLFZLFLEKLZBBK